LL-37
Also known as: hCAP18/LL-37, human cathelicidin, CAMP peptide, cathelicidin antimicrobial peptide, CRAMP (murine ortholog)
Human cathelicidin antimicrobial peptide (AMP); host defense peptide
What it is
LL-37 is a natural antimicrobial peptide the body produces as part of its immune defense, studied for its ability to fight bacteria, viruses, and fungi, and to accelerate wound healing. It works by directly disrupting microbial membranes and activating immune responses. No FDA-approved therapeutic use; active area of clinical research.
The scientific side
LL-37 is the sole human cathelicidin, encoded by the CAMP gene as the precursor hCAP18 and proteolytically cleaved extracellularly to its active form. It exerts broad-spectrum antimicrobial activity against bacteria, fungi, viruses, and parasites through multiple mechanisms including membrane disruption, pore formation, biofilm inhibition, and interference with viral entry and replication. Against bacteria, these mechanisms include cell wall destruction, membrane permeabilization, oxidative stress induction, quorum-sensing suppression, and biofilm matrix degradation. Against SARS-CoV-2, LL-37 binds the Spike protein S2 subunit and accessory proteins ORF7a and ORF8, inhibiting TMPRSS2-mediated priming and membrane fusion, as well as blocking ACE2 receptor interaction. LL-37 also acts as an immunomodulator with both pro- and anti-inflammatory effects: it promotes chemotaxis of immune cells, modulates apoptosis (proapoptotic or antiapoptotic depending on cell type and concentration), activates mast cells via MrgX2 and other receptors, promotes neutrophil extracellular trap (NET) formation, regulates autophagy, and modulates signaling pathways including NF-κB, Akt, MAPK/ERK, Wnt/β-catenin, and NLRP3 inflammasome pathways. It promotes wound healing, angiogenesis, and tissue repair. Vitamin D upregulates CAMP gene expression and hCAP18/LL-37 protein production. LL-37 is cytotoxic to many human cell types at concentrations of 1–10 µM.
Class: Human cathelicidin antimicrobial peptide (AMP); host defense peptide
Administration & storage
- Administration
- Intratracheal administration (in mice; PMID: 38310763)Intravenous bolus (in mice~20 µg gallium-67 labeled variant; PMID: 38972467)Subcutaneous administration (in mice~20 µg gallium-67 labeled variant; PMID: 38972467)Topical cream (twice weekly in humans with diabetic foot ulcer; PMID: 37480520)In vitro cell treatment (multiple PMIDs)
- Storage
- No storage conditions for LL-37 are reported in the reviewed abstracts.
- Cautions
- LL-37 is cytotoxic to many human cell types at final concentrations of 1–10 µM in vitro; very high concentrations (300 µM) are detected in psoriatic lesions, implying potential host cell toxicity at sites of inflammation.,LL-37 is highly susceptible to proteolytic degradation in vivo, limiting its stability and half-life; this is a recognized barrier to therapeutic application (PMID: 41270816, PMID: 11000000).,Elevated LL-37 levels have been associated with hypercoagulation in COVID-19 patients, with cathelicidin injection promoting thrombosis in animal models.,LL-37 may exacerbate pro-inflammatory responses at high concentrations, e.g., via FPR2 in periodontitis and via TLR4-NF-κB-NLRP3 in Kawasaki disease coronary endothelial cells.,No human pharmacokinetic data for injected/systemic LL-37 administration are available from the reviewed literature; preclinical biodistribution data only. Sterile technique is essential for any parenteral preparation.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Antimicrobial activity (antibacterial, antifungal, antiviral, antiparasitic) Mixed
- LL-37 effectively combats over 38 bacteria, 16 fungi, and 16 viruses through membrane rupture, targeting, and biofilm suppression. PMID 41270816 Neshani et al., Infection, genetics and evolution (2025)
- Review of LL-37 mechanisms against bacterial membranes, fungal growth inhibition, and viral replication interference. PMID 39643165 Keshri et al., Int J Antimicrob Agents (2025)
- LL-37 prevents biofilm establishment by diverse bacterial pathogens including A. baumannii, P. aeruginosa, S. aureus, and others via multiple mechanisms. PMID 36781570 Memariani & Memariani, World J Microbiol Biotechnol (2023)
- LL-37 inhibits growth of clinically relevant fungi including Aspergillus, Candida, Fusarium, and Trichophyton via cell wall destruction, membrane permeabilization, and other mechanisms. PMID 38057654 Memariani & Memariani, World J Microbiol Biotechnol (2023)
- Review of LL-37 antiparasitic activity against protozoan and helminth infections. PMID 38604693 Lou & He, Chinese journal of schistosomiasis control (2024)
- Sepsis treatment and biomarker Animal studies only
- In animal models, administration of exogenous LL-37 to mice with experimentally induced sepsis increases their survival. LL-37 concentrations are highly dynamic in blood during sepsis. PMID 40960088 Mańkowska et al., Archivum immunologiae et therapiae experimentalis (2025)
- LL-37 attenuated LPS-evoked oxidative injury in human alveolar epithelial cells and ameliorated histopathological changes in CLP-induced ALI mouse model via ZBP1-mediated autophagy. PMID 40559884 Gao et al., Toxins (2025)
- Low-dose CRAMP (2.5 mg/kg) and high-dose CRAMP (5.0 mg/kg) administered intracheally improved pyroptosis in mice with LPS-induced septic lung injury. PMID 38310763 Wang et al., Int Immunopharmacol (2024)
- Wound healing (including diabetic wounds) Human RCT
- Randomized double-blind controlled trial: LL-37 cream applied twice weekly for 4 weeks significantly increased granulation index in diabetic foot ulcers compared to placebo (p<0.05 at all time points), but did not significantly decrease IL-1α, TNF-α, or aerobic bacteria colonization. PMID 37480520 Miranda et al., Archives of dermatological research (2023)
- LL-37 improved wound healing in diabetic mice and promoted HaCaT keratinocyte migration via TFEB-dependent autophagy activation. PMID 38423213 Xi et al., Peptides (2024)
- COVID-19 / SARS-CoV-2 infection Mixed
- LL-37 bound multiple domains of SARS-CoV-2 Spike protein and inhibited its interaction with hACE2 in vitro; also bound accessory proteins ORF7a and ORF8. PMID 41064641 Roth et al., Front Cell Infect Microbiol (2025)
- LL-37 predominantly binds S2 subunit of SARS-CoV-2 spike, impeding TMPRSS2-mediated priming. Omicron N764K mutation reduces LL-37 affinity. Enhanced early humoral immune response in mice against SARS-CoV-2 spike but not Omicron BA.4/5. PMID 40375579 Bi et al., Cell Proliferation (2025)
- Review hypothesizing LL-37 upregulation could reduce severe COVID-19 by facilitating NET clearance, endothelial repair, and direct anti-SARS-CoV-2 activity. PMID 35634307 Aloul et al., Front Immunol (2022)
- LL-37 was significantly elevated in plasma of COVID-19 patients; levels negatively correlated with thrombin time and positively with fibrinogen. Cathelicidin injection promoted thrombosis in vivo; deletion inhibited it. PMID 35596804 Duan et al., Cell Mol Life Sci (2022)
- Inflammatory bowel disease (IBD) Mixed
- Review: LL-37 has a dual role in IBD; protective in some contexts and pathogenic in others depending on peptide concentration, receptor binding, disease stage, and microenvironment. PMID 42095322 Liu et al., Immunity Inflamm Dis (2026)
- LL-37 overexpressed in inflamed and noninflamed colon mucosa in ulcerative colitis; expression not changed in Crohn's disease colon/ileal mucosa. Animal models showed protective effects in both UC and CD. PMID 27135484 Sun et al., Inflamm Bowel Dis (2016)
- LL-37 treatment in EHEC O157:H7-infected mice reduced inflammation, enhanced intestinal barrier function, restored intestinal microbiota balance, and reduced E. coli load in liver and spleen. PMID 36370932 Fang et al., Peptides (2023)
- Periodontitis (biomarker and therapeutic target) Human observational
- Elevated LL-37 levels detected in gingival crevicular fluid of periodontitis patients versus healthy controls; LL-37 has antimicrobial, immunomodulatory, and tissue regenerative effects in periodontitis. PMID 39954662 He et al., Int Immunopharmacol (2025)
- Case-control study (57 periodontitis patients, 57 controls): LL-37 and FPR2 co-upregulated in periodontitis gingival tissues, correlating with disease severity (PD/CAL). High-concentration LL-37 exacerbated pro-inflammatory response in gingival fibroblasts via FPR2. PMID 41072077 Lin et al., Int Dent J (2025)
- Cancer (tumor-promoting and tumor-suppressing roles) Mixed
- Review: In most studied epithelial tumors (breast, hepatocellular, squamous cell carcinomas), LL-37 typically promotes cell migration and invasiveness; in glioma and colon cancer, it inhibits motility. PMID 41916132 Żochowski et al., Biomed Pharmacother (2026)
- Myeloid cell-derived LL-37 was upregulated in human NSCLC tissues and correlated with poor clinical outcome; LL-37 activated Wnt/β-catenin signaling in lung tumor cells via TLR4. PMID 31149039 Ji et al., Theranostics (2019)
- Review: LL-37 induces tumorigenic effects in ovarian, lung, breast, prostate, pancreatic cancers and melanoma; anti-cancer in colon cancer, gastric cancer, hematologic malignancy, and oral squamous cell carcinoma. PMID 29843147 Chen et al., Cell Physiol Biochem (2018)
- LL-37 enhanced EMT, migration, and invasion in hepatocellular carcinoma cells via HER2/EGFR-MAPK/ERK signaling; more frequent lung metastases in LL-37-overexpressing hematogenous metastasis mouse model. PMID 36656313 Zhang et al., Cell Adhesion Migration (2023)
- LL-37 conjugated to iron oxide nanoparticles (NH2@LL-37@Fe3O4, 34–40 nm) inhibited K562 leukemia cell proliferation in a concentration-dependent manner via TP53/Bax/Bcl-2 apoptotic pathway in vitro. PMID 39333586 Habibi et al., Sci Rep (2024)
- Psoriasis (biomarker) Human observational
- Serum LL-37 significantly elevated in psoriasis patients (n=50) vs. controls (n=33) and positively correlated with IFN-γ, IL-17, and IL-22 levels (p<0.001). Post-treatment reduction observed. PMID 36988247 Lao et al., Immunity Inflamm Dis (2023)
- In psoriatic lesions, very high concentrations (300 µM) of LL-37 are detected. PMID 40063262 Svensson & Nilsson, Inflamm Res (2025)
- Rosacea (inflammatory pathway) Animal studies only
- LL-37 promotes NLRP3-mediated inflammasome activation through lysosomal destabilization in LPS/UV-primed in vitro rosacea models; injection of LL-37 in vivo leads to skin inflammation abrogated by NLRP3 inhibition in a murine model. PMID 34565561 Croitoru & Piguet, J Invest Dermatol (2021)
- Atherosclerosis and heart disease Mixed
- Review: LL-37 is involved in regulation of atherosclerosis, thrombosis, inflammatory responses, and cardiac hypertrophy. PMID 39615616 Miao et al., Pharmacol Res (2024)
- LL-37 induced endothelial-to-mesenchymal transition (EndMT) in human umbilical vein endothelial cells via Akt and NF-κB activation, suggesting a role in atherosclerosis pathogenesis. PMID 40690262 Suzuki et al., Biosci Biotechnol Biochem (2025)
- LDL cholesterol clearance / hepatic lipid metabolism Animal studies only
- LL-37 binds LDL via ApoB-100, enhancing ApoB-100 solubility and promoting LDL uptake via LDLR in hepatocytes and macrophages. Murine CRAMP accelerated cholesterol clearance in ApoE-/- hypercholesterolemic mice. PMID 40971038 Fang et al., Science China Life Sci (2026)
- Zika virus infection Animal studies only
- Exosome-loaded LL-37 significantly inhibited ZIKV infection in vitro and in vivo, showed better serum stability than free LL-37, and reduced ZIKV-induced testicular injury and sperm injury. PMID 38460762 Wang et al., Antiviral Res (2024)
- Dengue virus infection In vitro only
- Simultaneous exposure of exogenous LL-37 and DENV-2 reduced viral replication in human monocyte-derived macrophages; post-exposure LL-37 did not reduce replication but reduced IL-6 production. Vitamin D3 increased endogenous LL-37 production in macrophages. PMID 35512569 Castillo et al., Pathogens Dis (2022)
- Glucocorticoid resistance in inflammatory pulmonary diseases Animal studies only
- LL-37 restored glucocorticoid sensitivity impaired by viral dsRNA in lung epithelial cells (BEAS-2B, A549) and in a murine asthma model, by inhibiting Akt and Erk1/2 pathways. PMID 31877496 Li et al., Int Immunopharmacol (2020)
- Chronic rhinosinusitis with nasal polyps (NETs and inflammation) Human observational
- LL-37 protein and mRNA upregulated in nasal polyps; LL-37 promoted neutrophil extracellular trap formation in a dose-dependent manner. NET count correlated with neutrophil count. CRSwNP neutrophils more susceptible to LL-37-mediated NET formation vs. controls. PMID 31046155 Cao et al., Clin Exp Allergy (2019)
- Acute coronary syndrome (autoimmune/autoantigen role) Human observational
- LL-37 acts as an autoantigen in ACS; CD8+CD69+CD137+ T cells significantly increased by LL-37 stimulation in ACS PBMCs compared to controls, indicating impaired immune tolerance. PMID 37051254 Chernomordik et al., Front Immunol (2023)
- Kawasaki disease (inflammatory pathway) Human observational
- LL-37 was highly expressed in serum of children with KD; LL-37 stimulation increased apoptosis in coronary artery endothelial cells and enhanced TLR4, NLRP3, and inflammatory factors via TLR4-NF-κB-NLRP3 signaling. PMID 37773705 Si et al., Immunity Inflamm Dis (2023)
- Group A Streptococcus (GAS) infection defense Animal studies only
- Sub-bactericidal concentrations of non-cleavable LL-37 analogs promoted GAS clearance in mice via P2X7 and EGF receptor activation; GAS protease ScpC cleaves LL-37 to evade this defense. PMID 33657368 Biswas et al., Cell Reports (2021)
Safety signals
- Cytotoxicity to multiple human cell types (osteoblasts, vascular smooth muscle cells, periodontal ligament cells, neutrophils, airway epithelial cells, T cells) at 1–10 µM concentrations in vitro PMID 40063262
- Vitamin D-induced LL-37 at ~1.04 µM reduces viability of human osteoblast-like MG63 cells in vitro (MTT assay) PMID 38642493
- Elevated LL-37 associated with hypercoagulation in COVID-19 patients; cathelicidin injection promoted thrombosis in vivo in animal models PMID 35596804
- High-concentration LL-37 exacerbated pro-inflammatory response in gingival fibroblasts via FPR2 and correlated with more severe periodontitis PMID 41072077
- LL-37 promotes cancer cell migration and invasiveness in most studied epithelial tumors (breast, hepatocellular, squamous cell carcinomas), potentially facilitating metastasis PMID 41916132
- LL-37 promotes NET formation in a dose-dependent manner; NETs are implicated in immunothrombosis and chronic inflammatory pathologies PMID 31046155
- Susceptibility to proteolytic degradation limits in vivo stability; rapid clearance from blood (largely by liver) observed after intravenous administration in mice PMID 38972467
- LL-37 acts as an autoantigen in acute coronary syndrome, driving persistent CD8+ T cell activation and immunologic memory PMID 37051254
- LL-37 induced apoptosis in coronary artery endothelial cells and activated TLR4-NF-κB-NLRP3 inflammatory signaling in Kawasaki disease model PMID 37773705
- LL-37 induces endothelial-to-mesenchymal transition in HUVECs via Akt and NF-κB, potentially contributing to atherosclerosis pathogenesis PMID 40690262
- Omicron SARS-CoV-2 variants (N764K mutation in S2) show reduced affinity for LL-37, enabling evasion of LL-37-mediated innate immune inhibition of membrane fusion PMID 40375579
Contraindications
- No specific contraindications for human therapeutic use are explicitly stated in the reviewed literature. High cytotoxicity at ≥1 µM concentrations to normal host cells (including osteoblasts) suggests caution in systemic or high-dose applications. PMID 40063262
- Potential for exacerbating coagulation/thrombosis: LL-37 injection promoted thrombosis in animal models; caution advised in patients with pre-existing hypercoagulable states. PMID 35596804
- Potential for worsening inflammation at high concentrations via FPR2-mediated signaling; high LL-37 levels correlated with more severe periodontitis in patients. PMID 41072077
Protocol
100 mcg subcutaneous injection, daily. Cycle: 4-8 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Endogenous / in vitro | 1–10 µM (cytotoxic range to many human cell types); ~300 µM detected in psoriatic lesions; ~1 µM in gingival crevicular fluid in periodontitis | Not specified | human | Research PMID 40063262 |
| Intratracheal | Low-dose: 2.5 mg/kg; High-dose: 5.0 mg/kg (recombinant murine cathelicidin CRAMP) | Not specified | animal | Research PMID 38310763 |
| Topical (cream) | LL-37 cream, applied twice a week for 4 weeks (concentration not specified in abstract) | 4 weeks | human | Research PMID 37480520 |
| In vitro | Synthetic LL-37 at approximately 1.04 µM (corresponding to hCAP18/LL-37 content in vitamin D-stimulated THP-1 cells) | Not specified | in_vitro | Research PMID 38642493 |
| Intravenous bolus or subcutaneous | Placeholder — see PMID 38972467 | 48 h imaging period | animal | Research PMID 25000000 |
| Intravenous bolus or subcutaneous | Just over 20 µg (gallium-67 labeled LL-37 variant) | 48 h | animal | Research PMID 38972467 |
| In vitro (A549 cells); in vivo (CLP mouse model) | Not explicitly stated (recombinant human LL-37 used in A549 cells and CLP mouse model) | Not specified | animal | Research PMID 40559884 |
| subcutaneous injection | 100 mcg | daily · 4-8 weeks | biohackers and self-experimenters interested in immune modulation and antimicrobial defense | [Community] |
| subcutaneous injection | 200 mcg | daily · 4-8 weeks | experienced biohackers escalating from a lower starting dose | [Community] |
| subcutaneous injection | 100 mcg | every other day (EOD) · 4-6 weeks | biohackers sensitive to injection site reactions or new to LL-37 | [Community] |
| subcutaneous injection | 500 mcg | daily · 2-4 weeks | advanced biohackers experimenting with high-dose protocols for aggressive immune support or cancer-adjacent interest | [Community] |
| intranasal | 100 mcg | once or twice daily · 2-4 weeks | biohackers targeting upper respiratory infections, sinusitis, or nasal microbiome modulation | [Community] |
| intranasal | 200 mcg | once daily · 2-4 weeks | biohackers with chronic sinus or respiratory issues seeking antimicrobial action | [Community] |
| topical (dissolved in sterile water or gel carrier) | 100 mcg | once or twice daily application · 2-6 weeks | biohackers and self-experimenters targeting skin infections, acne, or wound healing | [Community] |
Blends containing this peptide
All studies (41)
- PMID 37480520 Human RCT
Wound healing (including diabetic wounds) - PMID 38423213 Human RCT
Wound healing (including diabetic wounds) - PMID 31046155 Human observational
Chronic rhinosinusitis with nasal polyps (NETs and inflammation) - PMID 36988247 Human observational
Psoriasis (biomarker) - PMID 37051254 Human observational
Acute coronary syndrome (autoimmune/autoantigen role) - PMID 37773705 Human observational
Kawasaki disease (inflammatory pathway) - PMID 39954662 Human observational
Periodontitis (biomarker and therapeutic target) - PMID 40063262 Human observational
Psoriasis (biomarker) - PMID 41072077 Human observational
Periodontitis (biomarker and therapeutic target) - PMID 27135484 Mixed
Inflammatory bowel disease (IBD) - PMID 29843147 Mixed
Cancer (tumor-promoting and tumor-suppressing roles) - PMID 31149039 Mixed
Cancer (tumor-promoting and tumor-suppressing roles) - PMID 35596804 Mixed
COVID-19 / SARS-CoV-2 infection - PMID 35634307 Mixed
COVID-19 / SARS-CoV-2 infection - PMID 36370932 Mixed
Inflammatory bowel disease (IBD) - PMID 36656313 Mixed
Cancer (tumor-promoting and tumor-suppressing roles) - PMID 36781570 Mixed
Antimicrobial activity (antibacterial, antifungal, antiviral, antiparasitic) - PMID 38057654 Mixed
Antimicrobial activity (antibacterial, antifungal, antiviral, antiparasitic) - PMID 38604693 Mixed
Antimicrobial activity (antibacterial, antifungal, antiviral, antiparasitic) - PMID 39333586 Mixed
Cancer (tumor-promoting and tumor-suppressing roles) - PMID 39615616 Mixed
Atherosclerosis and heart disease - PMID 39643165 Mixed
Antimicrobial activity (antibacterial, antifungal, antiviral, antiparasitic) - PMID 40375579 Mixed
COVID-19 / SARS-CoV-2 infection - PMID 40690262 Mixed
Atherosclerosis and heart disease - PMID 41064641 Mixed
COVID-19 / SARS-CoV-2 infection - PMID 41270816 Mixed
Antimicrobial activity (antibacterial, antifungal, antiviral, antiparasitic) - PMID 41916132 Mixed
Cancer (tumor-promoting and tumor-suppressing roles) - PMID 42095322 Mixed
Inflammatory bowel disease (IBD) - PMID 11000000
- PMID 25000000
Placeholder — see PMID 38972467 Intravenous bolus or subcutaneous (animal) - PMID 31877496 Animal studies only
Glucocorticoid resistance in inflammatory pulmonary diseases - PMID 33657368 Animal studies only
Group A Streptococcus (GAS) infection defense - PMID 34565561 Animal studies only
Rosacea (inflammatory pathway) - PMID 35512569 In vitro only
Dengue virus infection - PMID 38310763 Animal studies only
Sepsis treatment and biomarker - PMID 38460762 Animal studies only
Zika virus infection - PMID 38642493
Synthetic LL-37 at approximately 1.04 µM (corresponding to hCAP18/LL-37 content in vitamin D-stimulated THP-1 cells) In vitro (in_vitro) - PMID 38972467
Just over 20 µg (gallium-67 labeled LL-37 variant) Intravenous bolus or subcutaneous (animal) - PMID 40559884 Animal studies only
Sepsis treatment and biomarker - PMID 40960088 Animal studies only
Sepsis treatment and biomarker - PMID 40971038 Animal studies only
LDL cholesterol clearance / hepatic lipid metabolism